Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss

Plus Therapeutics' stock experienced a significant drop of 14.13% in pre-market trading on June 3, 2025, marking a notable decline in its share price.

Plus Therapeutics reported a substantial loss of $17.4 million in its first quarter, which contributed to the decline in its stock price. The company's earnings miss was a key factor in the market's negative reaction, as investors had anticipated better financial performance.

The company's Q1 financial results, released on May 30, highlighted the earnings miss and recent business developments. This news further impacted investor sentiment, leading to the pre-market drop in stock price.

Looking ahead, Plus Therapeutics is scheduled to report its Q2 earnings on August 13, 2025. Investors will be closely monitoring the company's performance in the coming quarters to gauge its recovery and future prospects.